A multicomponent food supplement with bromelain, escin, and selenium in patients with urological medical disorders

S.E. Aragona, M. Zanoni, O. Sedigh, G. Savoca, G. Ciprandi, the Urosurvey Study

Article ID: 5436
Vol 36, Issue 2S2, 2022
DOI: https://doi.org/10.23812/j.biol.regul.homeost.agents.202236.2S2.13
Received: 9 May 2022; Accepted: 9 May 2022; Available online: 9 May 2022; Issue release: 9 May 2022

Abstract

Urological disorders are very common and affect any age. The most common medical conditions include cystitis, urolithiasis, renal colic, and prostatitis. Broser® is a food supplement containing bromelain, escin,and selenium. Its efficacy has been positively tested in patients with otorhinolaryngological disorders.Therefore, the present clinical experience investigated the efficacy and safety of this product in patients with medical urological disorders and treated with standard therapy. The add-on Broser® course lasted 2 weeks. The oral nutraceutical was taken following the specific indications, such as two tablets/daily. Patients were visited at baseline (T0) and after the treatment (T1). Patients in Group A had to take Broser® one tablet b.i.d. per 20 days. Evaluation parameters were the following signs and symptoms: pain, functional powerlessness, fever, oedema, malaise, dysuria, and infection severity. Globally, 1,204 patients participated in this clinical experience. The median age was 52 years. The food supplement significantly reduced the symptom severity and the incidence of symptoms. In conclusion, the present clinical experience demonstrated that the add-on therapy with Broser® significantly reduced the severity and incidence of urological complaints. Therefore, this food supplement could be fruitfully used in clinical practice.


Keywords

medical urological disorders;bromelain;escin;selenium;real-life study


References

Supporting Agencies



Copyright (c) 2022 S.E. Aragona, M. Zanoni, O. Sedigh, G. Savoca, G. Ciprandi, the Urosurvey Study Group




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).